Evan Seigerman, BMO Capital Markets senior pharma analyst, joins 'Power Lunch' to discuss Seigerman's thoughts on Eli Lilly's earnings results. Got a confidential news tip? We want to hear from you.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results